Original articleExtending half-life in coagulation factors: where do we stand?
References (29)
- et al.
Molecular genetics of von Willebrand disease
Blood
(1992) - et al.
Clearance mechanisms of von Willebrand factor and factor VIII
J Thromb Haemost
(2007) - et al.
The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein
J Biol Chem
(1999) - et al.
Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism
J Biol Chem
(1999) - et al.
LDL receptor cooperates with LDL receptor-mediated protein in regulating plasma levels of coagulation factor VIII in vivo
Blood
(2005) - et al.
Cell surface heparan sulphate proteoglycans participate in factor VIII catabolism mediate by low density lipoprotein receptor-related protein
J Biol Chem
(2001) Peptide and protein PEGylation: a review of problems and solutions
Biomaterials
(2001)- et al.
Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes
Blood
(2006) - et al.
Crystal structure of human factor VIII: implications for the formation of the factor IXa factor VIIIa complex
Structure
(2008) - et al.
The tertiary structure and domain organization of coagulation factor VIII
Blood
(2008)
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
J Thromb Haemost
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn
Trends Cell Biol
Blood coagulation factor VIII: an overview
J Biosci
Clearance of von Willebrand factor
Thromb Haemost
Cited by (24)
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: A randomized first human dose trial
2015, Journal of Thrombosis and HaemostasisA von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice
2014, BloodCitation Excerpt :However, a S764-R1035 proteolytic fragment binds FVIII with markedly reduced affinity (KD = 48.5 nM) compared with longer VWF fragments.21,22 Several approaches have attempted to engineer FVIII with an extended plasma half-life (t1/2).23-26 Recombinant human B-domain deleted FVIII infused into a C57BL/6 mouse has a similar t1/2 (4.3 hours) to that of endogenous murine VWF (∼4.5 hours).25,27,28
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor
2014, Thrombosis ResearchCitation Excerpt :These patients are then treated with bypassing agents, i.e. plasma-derived activated prothrombin complex concentrate (pd-aPCC) or recombinant Factor VIIa (rFVIIa). Prophylactic therapy with either replacement or bypassing agents requires frequent i.v. injections with negative implications for adherence to therapy and the general quality of life for patients [1]. Subcutaneous injections and reduced dosing frequency are thus highly desired options for haemophilia treatment, which may be attainable with a therapy that involves an antibody having high bioavailability and long half-life.
Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII
2012, Journal of Biological ChemistryCitation Excerpt :FVIII is found in plasma in a tight complex with its carrier protein von Willebrand factor (4). The role of von Willebrand factor is to protect FVIII from rapid clearance from the circulation and to prevent premature binding of FVIII to its ligands (5, 6). Proteolytic cleavage between a3 and the A3 domain by thrombin results in the dissociation of the FVIII-von Willebrand factor complex (4).
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B
2011, BloodCitation Excerpt :Hemophilia treatment has a lifetime perspective, and ongoing safety surveillance of PEGylated products is warranted. Current management and prevention of bleeding episodes in patients with hemophilia B involves frequent and multiple injections of coagulation factors, because of their relatively short t[1/2].32 A typical dosing schedule is therefore inconvenient, making compliance difficult and impacts patient quality of life.32